logo
Plus   Neg
Share
Email

Seattle Genetics Reports Positive Results From HER2CLIMB Trial Of TUKYSA

Seattle Genetics, Inc. (SGEN) reported positive results from exploratory analyses of intracranial efficacy, including survival, in patients with HER2-positive metastatic breast cancer who had stable or active brain metastases in the HER2CLIMB pivotal trial
of TUKYSA. TUKYSA in combination with trastuzumab and capecitabine was approved by the FDA in April for adult patients with advanced unresectable or metastatic HER2-positive breast cancer.

"These additional analyses, together with the primary analysis of HER2CLIMB, show TUKYSA is active for patients with and without disease that has spread to the brain," said Roger Dansey, Chief Medical Officer of Seattle Genetics.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Volkswagen Group were gaining around 3 percent in German trading after the automotive giant Thursday reported market recovery in the third quarter with improved deliveries in the month of September. For the first nine months of fiscal 2020, the company, meanwhile reported sharply lower earnings with weak revenues and sales volume. Comcast Corp. on Thursday reported a 37 percent decline in profit for the third quarter from last year, hurt primarily by revenue decline at NBCUniversal. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also declared a quarterly dividend. In the pre-market trade, CMCSA is trading at $42.83, up $0.85 or 2.02 percent. Regeneron announced positive results from its late stage COVID-19 outpatient trial, indicating that its antibody cocktail therapy significantly reduced virus levels and need for further medical attention. The trial results showed that investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints.
Follow RTT